Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer
NCT01009983
Terminated
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Other find tumor cells and help kill them or carry tumor-killing substances to them. Giving panitumumab together with paclitaxel and carboplatin may be a better... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/03/2018
Locations: Ochsner Clinic Foundation, New Orleans, Louisiana +1 locations
Conditions: Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Register for Updates
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
NCT01026467
Completed
This phase II trial is studying how well a frailty index and geriatric assessment works in predicting toxicity to front-line chemotherapy in treating patients with stage IV non-small cell lung cancer. A frailty index and geriatric assessment prior to treatment may help identify a better treatment regimen
Gender:
ALL
Ages:
All
Trial Updated:
07/02/2018
Locations: Syracuse VA Medical Center, Syracuse, New York +1 locations
Conditions: Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Register for Updates
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.
NCT01732640
Terminated
Trial Objectives: The objective is to investigate the efficacy and safety of afatinib with induction chemotherapy in primary unresected patients with locally advanced, HPV-negative, stage III or IVa/b HNSCC including oral cavity, oropharynx, hypopharynx, or larynx. Primary Objective Phase I The primary objective of the phase I portion of the trial is to determine the maximum tolerated dose (MTD) or the recommended phase II dose of daily oral afatinib that is safe in combination with carboplati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2018
Locations: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland +1 locations
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer
NCT02748889
Terminated
This is an open-label study with two parts, a Phase I study and a randomized Phase II study. This study will be conducted at approximately ten sites in the United States. Approximately 178 patients will be enrolled in this trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2018
Locations: Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia
Conditions: Small Cell Lung Cancer ( SCLC )
Register for Updates
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT01041781
Terminated
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed disodium and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving gemcitabine hydrochloride or pemetrexed disodium together with carboplatin is more effective with or without celecoxib in treatin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2018
Locations: Regional Medical Center, Anniston, Alabama +399 locations
Conditions: Lung Cancer
Register for Updates
RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
NCT01009346
Terminated
1.Phase I: To estimate the Maximum Tolerated Dose (MTD) of RAD001 in combination with cetuximab and cisplatin for treatment of metastatic squamous cell cancer of the head and neck (SCCHN). Secondary Objectives 1.To assess the toxicity of RAD001 in combination with weekly cetuximab and cisplatin on days 1 and 8 of each 28 day cycle in patients with recurrent or metastatic SCCHN,
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/22/2018
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Head and Neck Cancer
Register for Updates
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel
NCT01234038
Completed
The purpose of this study is to examine the overall survival of patients with Stage IV non-small cell lung cancer (NSCLC) treated with ISIS EIF4E Rx in combination with carboplatin and paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2018
Locations: Achieve Clinical Research, Birmingham, Alabama +28 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
NCT02122770
Completed
The primary purpose of this study is to assess the effect of multiple-dose administration of fluconazole on the single-dose intravenous (IV) pharmacokinetics (PK) of MLN4924; and to assess the effect of multiple-dose administration of itraconazole on the single-dose IV PK of MLN4924.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2018
Locations: Winship Cancer Institute at Emory University, Atlanta, Georgia +3 locations
Conditions: Advanced Solid Tumors
Register for Updates
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
NCT00527735
Completed
The purpose of the study is to determine whether ipilimumab given with paclitaxel/carboplatin has clinical benefit when compared with paclitaxel/carboplatin alone in patients with previously untreated lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2018
Locations: Birmingham Hematology & Oncology Assoc. Llc, Birmingham, Alabama +71 locations
Conditions: Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
Register for Updates
Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants
NCT00228319
Completed
The purpose of this study is to try and understand if there is added benefit or increased harm when antioxidant nutritional supplements are added to traditional chemotherapy in the treatment of ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/16/2018
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Ovarian Cancer
Register for Updates
Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer
NCT02252796
Terminated
This study will help researchers test the safety of hypofractionated dose of radiotherapy (HySBst) at different dose levels before or after chemo-radiation for Non Small Cell Lung Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/25/2018
Locations: West Virginia University Hospitals Mary Babb Randolph Cancer Center, Morgantown, West Virginia
Conditions: Non-small Cell Lung Cancer
Register for Updates
Salvage Ovarian FANG™ Vaccine + Carboplatinum
NCT01867086
Completed
This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with carboplatinum. All patients will have Vigil™ prepared and stored from ovarian tumor cells obtained at the time of primary surgical debulking. Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2/3 hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection, once every 3 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2018
Locations: Mary Crowley Cancer Research Centers, Dallas, Texas
Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Register for Updates